Race Attendees Donate Tears to Ascendant Diagnostics to Support Development of MelodyDX™, a New Test to Detect Breast Cancer

Share Article

Ascendant Diagnostics Team Attends 15th Annual Komen Ozark Race for the Cure®

Logo for Ascendant Diagnostics, LLC
Ascendant Diagnostics, LLC is developing the company’s first product, MelodyDx™, a pain-free, low-cost screening test that can detect the presence of early-stage breast cancer using the protein profile of a person’s tears.

Ascendant Diagnostics, LLC is developing the company’s first product, MelodyDx™, a pain-free, low-cost screening test that can detect the presence of early-stage breast cancer using the protein profile of a person’s tears.

The Komen Ozark Race for the Cure®, held Saturday, April 27th in Rogers, provided Ascendant Diagnostics the opportunity to set-up a tear collection booth in order to gather samples from race day attendees. Tear collection requires a simple saline wash of the surface of the eye. These anonymous samples will be used for test development in Ascendant Diagnostics’ research laboratory. Dr. Anna Daily, Chief Scientist, led the effort, and was assisted in tear collection by nurses and support staff from Highlands Oncology and The Breast Center. Volunteers helped to answer questions about the company and the collection process, as well as recruit volunteers from the race day crowds.

Ascendant Diagnostics currently is conducting clinical studies with five clinics nationwide, two of which are located in Northwest Arkansas. The Breast Center is collecting samples from 300 individuals who are undergoing a biopsy for evaluation of a suspicious mass, and Highlands Oncology is collecting samples from 300 individuals who are being treated for metastatic breast cancer. With these two clinics meeting the need for samples collected from patients with masses as well as breast cancer, the company’s current greatest need was to fill the “tear bank” with samples for general population studies, a step necessary for commercialization of a diagnostic test.

Saturday’s event, in which 220 tear samples were volunteered, provided an excellent start towards generating Ascendant Diagnostics’ tear bank. Tear samples were also collected from men, a population for whom there is currently no screening, as well as from breast cancer survivors. These samples will be used in future research applications of MelodyDX™.

Ascendant Diagnostics’ vision is to greatly increase the accuracy of cancer diagnostics, enable detection of disease at the earliest possible stage, and improve patient compliance through the use of non-invasive, pain-free diagnostic tools. The company's first product, MelodyDx, is a patent pending, non-invasive, biomarker panel for the detection of breast cancer, which detects differences in proteins present in human tears. The goal for MelodyDx is to increase breast cancer detection at earlier stages while at the same time reducing unnecessary exposure to radiation and painful biopsy procedures. Ascendant Diagnostics, LLC is a VIC Technology Venture Development portfolio company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Omid Moghadam
Ascendant Diagnostics, LLC
479-571-2592
Email >
Visit website